Last 48 quarters of trend data · Healthcare · Immunology Biotech
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 2.56 | — | 274.54 | 34.09 | 0.69 | — | — | — | 23.71 | — | 87.62 | 22.36 | 4.25 | 22.15 | 131.33 | 27.60 | — | 32.30 | — | — | 55.13 |
| — | — | — | — | -97.1% | — | — | — | +457.5% | — | -33.3% | -19.0% | — | -31.4% | — | — | — | — | — | — | — | |
| P/S Ratio | 2.19 | 64.61 | 43.36 | 76.23 | 0.60 | 8.02 | 7.06 | 5.51 | 0.00 | 7.92 | 5.24 | 8.50 | — | 4.74 | 4.47 | 10.87 | 7.68 | 5.15 | 6.66 | 7.57 | 5.49 |
| — | +705.6% | +513.9% | +1282.3% | +21908.5% | +1.2% | +34.7% | -35.1% | — | +67.1% | +17.4% | -21.8% | — | -8.0% | -33.0% | +43.6% | +39.8% | -61.6% | -17.5% | -33.1% | -51.4% | |
| P/B Ratio | 0.63 | 0.59 | 0.65 | 0.61 | 0.67 | 0.93 | 0.70 | — | — | — | — | — | 0.96 | 0.87 | 1.04 | 0.99 | 1.16 | 1.04 | 1.39 | 1.56 | 1.39 |
| — | -36.5% | -7.4% | — | — | — | — | — | — | — | — | — | -17.0% | -16.8% | -25.2% | -36.3% | -16.7% | -20.8% | -18.2% | -18.3% | -43.2% | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | 3.96 | — | — | 34.32 | 0.93 | 230.02 | — | — | — | — | — | — | — | 17.87 | 38.27 | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | 3.89 | — | — | 34.32 | 0.93 | 230.02 | — | — | — | — | — | — | — | 17.87 | 38.27 | — | — | — | — | — | 5.68 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -99.9% |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 97.3% | 51.5% | -185.8% | 26.0% | 99.9% | 84.8% | 92.8% | 81.7% | -49.6% | -55.5% | -15.8% | 518.5% | 100.0% | 95.3% | 97.2% | 100.0% | 95.6% | 14.1% | 98.1% | 24.6% | 99.4% |
| — | -39.3% | -300.3% | -68.2% | +301.6% | +252.7% | +687.7% | -84.2% | -149.6% | -158.3% | -116.3% | +418.5% | +4.6% | +573.6% | -1.0% | +306.8% | -3.8% | -85.7% | -1.8% | -75.4% | +1005.2% | |
| Operating Margin | 45.1% | -537.1% | -358.9% | -982.9% | 84.2% | -58.6% | -87.3% | -211.7% | -107.4% | -90.7% | -49.0% | -53.1% | 33.1% | -25.2% | -7.1% | -24.2% | -139.3% | -27.6% | -55.5% | -15.5% | -204.4% |
| — | -817.2% | -310.9% | -364.4% | +178.5% | +35.5% | -78.1% | -298.9% | -423.9% | -260.2% | -587.8% | -118.9% | +123.8% | +8.7% | +87.1% | -56.3% | +31.9% | +77.4% | -65.8% | +65.2% | -1807.9% | |
| Net Margin | 28.8% | -35.2% | 17.4% | 223.6% | 86.8% | -284.0% | -162.0% | -204.6% | 33.5% | -84.3% | 11.5% | 144.5% | -75.3% | 21.5% | 3.4% | 39.6% | -217.8% | 15.8% | -13.8% | -9.8% | 9.8% |
| — | +87.6% | +110.7% | +209.3% | +159.0% | -237.1% | -1503.8% | -241.6% | +144.5% | -491.5% | +239.2% | +264.7% | +65.4% | +36.0% | +124.6% | +505.9% | -2324.9% | +115.7% | +70.0% | -218.8% | +124.4% |
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 9.9% | -0.1% | 0.1% | 0.4% | 27.5% | -7.9% | -4.0% | — | — | — | — | — | 5.8% | 1.0% | 0.2% | 0.9% | -7.9% | 0.8% | -0.7% | -0.5% | 0.6% |
| — | +99.0% | +101.6% | — | — | — | — | — | — | — | — | — | +173.2% | +22.9% | +127.6% | +281.2% | -1378.1% | +133.0% | +70.0% | -244.4% | +128.9% | |
| ROA | 9.4% | -0.1% | 0.1% | 0.4% | 22.6% | -5.5% | -2.8% | — | — | — | — | — | 3.6% | 0.6% | 0.1% | 0.5% | -4.3% | 0.4% | -0.4% | -0.3% | 0.3% |
| — | +98.6% | +102.3% | — | — | — | — | — | — | — | — | — | +183.8% | +33.7% | +129.7% | +291.6% | -1474.2% | +135.9% | +67.8% | -256.5% | +130.7% | |
| ROIC | 11.8% | -1.0% | -1.0% | -1.5% | 20.5% | -1.3% | -1.6% | — | — | — | — | — | -2.0% | -0.9% | -0.3% | -0.5% | -4.9% | -1.5% | -3.7% | -1.7% | -207.9% |
| — | +23.6% | +36.9% | — | — | — | — | — | — | — | — | — | +58.3% | +39.6% | +91.2% | +72.3% | +97.7% | — | +88.2% | +83.4% | -10807.9% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — | — | 0.00 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| — | -68.7% | -38.8% | — | — | — | — | — | — | — | — | — | -60.4% | -36.0% | -34.4% | -34.9% | -14.7% | -16.4% | -13.3% | -9.7% | -7.8% | |
| Debt / EBITDA | 0.01 | — | — | 0.46 | 0.01 | 3.10 | — | — | — | — | — | — | — | 0.47 | 0.91 | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 20.15 | 46.49 | 32.82 | 30.48 | 20.15 | 8.63 | 8.08 | — | — | — | — | — | 9.02 | 8.91 | 8.49 | 7.95 | 8.11 | 8.38 | 8.23 | 8.44 | 8.58 |
| — | +439.0% | +306.3% | — | — | — | — | — | — | — | — | — | +11.2% | +6.3% | +3.1% | -5.8% | -5.5% | -3.8% | -7.4% | -3.8% | +1.5% | |
| Quick Ratio | 20.00 | 46.39 | 32.82 | 30.30 | 20.00 | 8.56 | 7.99 | — | — | — | — | — | 8.84 | 8.78 | 8.38 | 7.85 | 8.01 | 8.34 | 8.18 | 8.41 | 8.55 |
| — | +441.7% | +310.6% | — | — | — | — | — | — | — | — | — | +10.5% | +5.4% | +2.5% | -6.7% | -6.3% | -4.4% | -8.0% | -4.2% | +1.1% | |
| Interest Coverage | 136.71 | -330.91 | — | — | — | — | — | — | — | — | — | — | — | 104.24 | 21.69 | -12.48 | -47.32 | -17.62 | -6.86 | -5.03 | 1.31 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 48 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying LKFT stock.
Lakefront Biotherapeutics N.V.'s current P/E is 2.6x. The average P/E over the last 3 quarters is 103.1x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Lakefront Biotherapeutics N.V.'s current operating margin is 45.1%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Lakefront Biotherapeutics N.V.'s business trajectory between earnings reports.